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Targeted therapies on the basis of genomic aberrations analysis of the tumor have shown promising re-
sults in cancer prognosis and treatment. Regardless of tumor type, trials that match patients to targeted
therapies for their particular genomic aberrations have become a mainstream direction of therapeutic man-
agement of patients with cancer. Therefore, finding the subpopulation of patients who can most benefit from
an aberration-specific targeted therapy across multiple cancer types is important. We propose an adaptive
Bayesian clinical trial design for patient allocation and subpopulation identification. We start with a decision
theoretic approach, including a utility function and a probability model across all possible subpopulation
models. The main features of the proposed design and population finding methods are the use of a flexible
non-parametric Bayesian survival regression based on a random covariate-dependent partition of patients,
and decisions based on a flexible utility function that reflects the requirement of the clinicians appropriately
and realistically, and the adaptive allocation of patients to their superior treatments. Through extensive sim-
ulation studies, the new method is demonstrated to achieve desirable operating characteristics and compares
favorably against the alternatives.
Key words: Basket Trials; Bayesian adaptive designs; Subpopulation identification; Targeted
therapies;
1 Introduction
We propose an adaptive Bayesian clinical trial design for patient allocation and subpopulation finding in
a heterogeneous patient population in basket trials. We focus on the objectives of allocating patients to
their superior treatments and identifying a subpopulation of patients who are most likely to benefit from
the targeted therapy under consideration.
Recent developments of genomic profiling technologies (Snijders et al., 1998; Van de Vijver et al.,
2002; Barski and Zhao, 2009; Baladandayuthapani et al., 2010; Curtis et al., 2012; Xu et al., 2013) have
revolutionized the traditional diagnosis and treatment of cancer, leading to the development of targeted
therapies designed to target specific biomarkers and molecular pathways involved in the pathophysiology of
tumor initiation, metastasis, and drug resistance. For example, matching genomic aberrations with targeted
therapies has led to the use of trastuzumab on HER2+ breast cancer (Hudis, 2007), and the recommendation
against EGFR antibodies therapy for KRAS mutated colorectal cancer (Misale et al., 2012).
Some studies investigate the matching of tumor molecular alterations regardless of patient’s tumor type.
One of the first such trials was the IMPACT (Initiative for Molecular Profiling and Advanced Cancer
Therapy) study (Tsimberidou, 2009; Tsimberidou et al., 2012) which investigated the use of targeted agents
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matched with tumor molecular aberrations, and the following study IMPACT II (Tsimberidou, 2014) which
we describe in this paper. Such trials are known as “basket” trials. Similar later studies that followed
this example include the Lung-MAP (NCT021544490) and MATCH trials (Conley and Doroshow, 2014),
which enrolled patients into sub-studies based on their genomic alterations. Next-generation sequencing
(NGS) is used to identify patients with a specific genomic alteration or mutation, regardless of the specific
cancer. Patients are then enrolled in a trial to assess a particular molecularly targeted therapy. For instance,
BRAF is a relatively common mutation in patients with melanoma, for which Vemurafenib (Zelboraf) was
approved in 2011, but also occurs less frequently in other types of cancer. Researchers found that the
drug showed little efficacy in patients with BRAF- mutant colorectal cancer (Yang et al., 2012). Therefore,
finding the subpopulation of patients who can benefit from a mutation-specific experimental therapy across
multiple tumor types is important to “basket” trials. For example, Hyman et al. (2015) systematically
studied Vemurafenib in 122 patients with non-melanoma cancers harboring BRAF mutation and showed
that Vemurafenib had efficacy for patients with BRAF mutation in non-small-cell lung cancer and Erhheim-
Chester disease.
There is a growing literature to propose Bayesian approaches to identify subpopulations with enhanced
treatment effects. The general problem of reporting exceptions to an overall conclusion of a clinical study
is known as subgroup analysis. Dixon and Simon (1991) approach subgroup analysis as inference on
treatment/covariate interaction effects. Simon (2002) uses a similar approach with independent priors on
the interaction parameters. Sivaganesan et al. (2011) consider subgroup analysis as a model selection
problem with each covariate defining a family of models. Ruberg et al. (2010) and Foster et al. (2011)
develop tree-based algorithms to identify and evaluate subgroup effects by searching for regions with
substantially enhanced treatment effects compared to the average effect, averaging across the covariate
space. Sivaganesan et al. (2013) report subgroups within a Bayesian decision-theoretic framework. They
determine rules using an extension of a 0/1/K utility function. The utility function is based on the posterior
odds of subgroup models relative to the overall null and alternative models. Xu et al. (2014) identify
subgroups of patients with substantially different treatment effect based on a partition of the biomarker
space using a variation of Bayesian classification and regression tree.
Several recent clinical trials explore the use of Bayesian adaptive designs, in combination with subpop-
ulation finding designs. Prominent examples include the breast cancer trial ISPY-2 (Barker et al., 2009)
that uses indicators for several biomarkers and a MammaPrint risk score to define 14 subpopulations of
possible practical interest. The design graduates subpopulations, that is, recommends a future phase III
study; or drops subpopulations or treatment arms, that is, remove one of the 14 subpopulations or treat-
ment arms from further consideration. A similar design is the BATTLE study of Zhou et al. (2008) who
define 5 subpopulations of lung cancer patients based on biomarker profiles and proceed to adaptively al-
locate patients to alternative treatments. Another recent discussion is Berry et al. (2013) who include a
comparison of Bayesian adaptive designs, including a design based on a hierarchical model over different
subpopulations with a comparable design using Simon’s optimal two-stage design (Simon, 2012).
Some recent frequentist approaches use Bayesian methods to determine the adaptive enrichment to a
subpopulation that is most likely to benefit from a treatment (Simon and Simon, 2017). Brannath et al.
(2009) use posterior predictive probabilities to propose the adaptive enrichment in a seamless phase II/III
design. One of the challenges of such approaches is the control of (frequentist) operating characteristics.
Bretz et al. (2006), in a seamless phase II/III design with a selection among multiple candidate treatments
(doses), achieve the desired analytic error control by using combination tests to combine phase II and III
data and closed testing to control for multiplicities (the use of combination tests for error control is not
restricted to the special case of selecting one treatment arm or dose, but is fairly general across many
different design modifications). Quantifying errors and uncertainties for the more general problem of
inference for a benefiting subpopulation without pre-defined candidates is more challenging. Schnell et al.
(2016) and Schnell et al. (2017) propose a principled Bayesian approach by defining a notion of posterior
credible intervals for the estimated subpopulation.
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In this paper, we build on these earlier approaches and propose an adaptive Bayesian clinical trial
design for patient allocation in basket trials and a decision theoretic approach for subpopulation finding
in a heterogeneous patient population. Methodologically, we cast the problem as a decision problem and
separate the assumed sampling model and the decision problem. The important implication is that the
description of the desired subpopulation does not hinge on inference for parameters in the sampling model,
but is treated as a separate element in the statistical inference problem.
To proceed, we first introduce the IMPACT II study in Section 2. The proposed design is summarized
in Section 3. Next, in Section 4 we discuss the subpopulation selection. The discussion is possible without
reference to details of the probability model. In Section 5 we introduce the particular survival regression
model that we use and adaptive treatment allocation. Section 6 reports simulation studies. Finally, we
conclude with a discussion in Section 7.
2 IMPACT II
The proposed design is motivated by a clinical trial, IMPACT II (Tsimberidou, 2014; Tsimberidou et al.,
2014a), conducted at M.D. Anderson Cancer Center, based on data from multiple tumor types and molecu-
lar aberrations. The primary objective of the study is to determine if patients treated with a targeted therapy
(TT) that is selected based on mutational analysis of the tumor have longer progression-free survival than
those treated with other therapy (O). An important secondary aim is to identify a subpopulation of patients
who might most benefit from targeted therapy. In other words, identify a subpopulation that could best
define eligibility criteria for a future study of targeted therapy. Genomic analysis of tumor samples is per-
formed at the time of enrollment to identify tumor molecular aberrations and to assign treatment for every
individual patient.
Related observational data from a comparable patient population was reported in the IMPACT study
(Tsimberidou, 2009; Tsimberidou et al., 2012, 2014b). This previous exploratory, non-randomized study
was also performed at M.D. Anderson Cancer Center to test whether the use of targeted agents matches with
tumor molecular aberrations would improve clinical outcomes compared to the standard approach. Figure
1 summarizes the data from IMPACT as a Kaplan-Meier plot comparing TT versus O. The plot indicates
that patients who were treated with TT based on their tumor molecular profiling (labeled “matched” in the
figure) could have superior clinical outcomes compared to those who were treated with the conventional
approach (“non-matched”). However, this exploratory study was not randomized. Unknown confounding
factors may have contributed to higher rates of response and longer time to treatment failure and survival
in patients treated with TT compared to those treated with O. One possible confounding factor could be
a more favorable prognosis for patients treated with TT, such as EGFR mutation, which is well known to
confer a more favorable prognosis.
To overcome the limitations of the previous exploratory study IMPACT and to quantify the benefits
of assigning therapy based on mutational analysis over standard therapy, we use a randomized study for
the new trial: IMPACT II. For each enrolled patient we record a set of molecular aberrations, mi =
(mi1, . . . ,miq) and tumor type ci and we decide a treatment allocation zi ∈ {O,TT} for either targeted
therapy matched to a molecular aberration (TT), or other therapy, excluding targeted therapy (O). Impor-
tantly, the set of molecular aberrations that is recorded for each patient can vary substantially. We use
mij = NA for not recorded aberrations and mij ∈ {0, 1} for the absence or presence of recorded aberra-
tions, respectively. Note that mutations are not mutually exclusive and any patient could record multiple
aberrations. When a patient has multiple aberrations that are eligible for targeted therapy and is allocated
to TT, then the treatment is chosen based on an ordered list of mutations and drugs to treat the mutations
(this list is established by the tumor board which is established as part of the protocol). So we denote
mij = 1 is aberration j is targeted to treat for patient i, otherwise 0. Denote the combined covariate vector
by xi = (mi, ci). Finally, yi records progression free survival (PFS) time.
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Figure 1 Summary of observational, non-randomized data in IMPACT trial. The plot compares Kaplan
Meier plots for PFS under TT versus O. The lack of randomization prevents a causal interpretation.
The proposed design is based on a survival regression for PFS yi as a function ofxi and zi. Continuously
updated inference under this model is used for adaptive treatment allocation during the trial. Patients are
assigned to TT or O with probabilities that are related to the predictive distribution of PFS under the two
treatment arms. At the end of the trial we use inference under the same model to recommend a patient
population for a future trial.
3 Design
In IMPACT II, patients with metastatic cancer (any tumor type) and up to three prior therapies will undergo
tumor biopsy followed by molecular profiling. For each patient we record tumor type and presence/absence
of a set of molecular aberrations, including PIK3CA, PTEN, BRAF, MET, and “others” (including but not
limited to FGFR alterations). Patients with colorectal cancer and BRAF mutation were excluded because
of available data demonstrating that these inhibitors have no activity as single agents.
If at least one molecular alteration is identified, the patient will be treated as follows: if there is a U.S.
Food and Drug Administration (FDA)-approved drug within the labeled indication, the patient will receive
it; if there is no approved drug for the alteration and the tumor type, but there is a commercially available
targeted agent or appropriate clinical trial, patients will be randomly selected to receive targeted therapy
(TT) versus treatment not selected on the basis of genetic profiling (O). The allocation probabilities for the
random selection are specified as follows in an initial run-in phase and a later adaptive allocation phase of
the trial.
Run-in phase. We initiate the study with a run-in phase consisting of n0 = 100 randomized patients.
During this phase, patients who are selected for randomization (as described above) are equally randomized
to the two treatment arms TT vs. O.
Adaptive allocation. After the initial run-in of 100 patients, we introduce adaptive randomization for the
next n1 = 300 patients with a cohort size 50, allowing for a total of nmax = 400 randomized patients. For
the adaptive randomization, we use model-based posterior predictive probabilities. We discuss details of
the model specification later. Let pii denote the posterior probability, based on current data, that PFS time
under TT is greater than survival under O for patient i. See §5 for the evaluation of pii in the implemented
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probability model. Let zi ∈ {TT,O} denote the treatment allocation for patient i. For patients who are
selected for randomization (as described above), we use adaptive treatment allocation
p(zi = TT) =

p0 if pii < p0
pii if p0 < pii < p1
p1 if pii > p1.
(1)
We use p0 = 0.1 and p1 = 0.9.
Subpopulation finding. Most importantly, at the conclusion of the trial (6 months after 400 patients
accrue), we assess subpopulation-specific effects of targeted therapies. We report the subpopulations that
achieve the maximum benefit from targeted therapies. This assessment is based on the posterior expected
utilities of all possible subpopulations. The utilities depend on the characteristics of subpopulations as
well as the posterior probability model under an estimated regression for PFS. We shall evaluate the log
hazards ratio with respect to PFS. This will be measured from the time of initiation of treatment to disease
progression or death, as of the last follow-up visit. Details of the subpopulation finding are described
below, in §4.
4 Subpopulation Finding
Recall that mi = (mi1, . . . ,miq) denotes a vector of recorded molecular aberrations and xi = (mi, ci).
We characterize a subpopulation as a set of mutation-tumor pairs A = {a : a = (ja, ca)}, with ja ∈
{1, . . . , q} identifying a molecular aberration and ca ∈ {1, . . . , nc} denoting tumor type. Each a ∈ A
denotes a subgroup of patients with aberration mja = 1 and tumor ci = ca. For example, consider the
subpopulation report consisting of two subgroups, including patients with lung cancer and BRAF muta-
tion, and patients with breast cancer and PIK3CA mutation. We denote this subpopulation by {(BRAF,
Lung), (PIK3CA, Breast)}. If needed this characterization could incorporate other baseline covariates of
interest and/or higher order interactions of covariates to describe subpopulations. However, we do not use
such extensions in IMPACT II, restricting subsets to be characterized by mutation-tumor pairs (ja, ca).
We add two special cases of subpopulation reports: let A = A0 denote the report of no subpopulations
and no overall treatment effect; and let A = A1 denote the report of an overall treatment effect, but no
subpopulations. Note that A0 and A1 are actions, not assumptions about model parameters. In particular,
it is possible that one might report A0 even when there is a statistically significant treatment effect, but it
is too small to be of clinical relevance.
We use a decision theoretic approach to find an optimal decisionA?. We start by quantifying the relative
preferences across possible reports A?. That is, we specify a utility function. Let θ denote the parameters
of the underlying survival regression. We still do not need to make any specific assumptions about the
model, except for the existence of such a model. Given parameter vector θ and covariate vector x, we
assume that there is a sampling model p(y | z,x,θ) for PFS. A utility function is a function u(A,θ) for
an assumed action A and a hypothetical true parameter vector θ. In general the utility function could also
depend on observed or future data, but dependence on (A,θ) suffices for the upcoming application.
We define a utility function based on the notion that a clinically important subpopulation should show
a significant treatment effect for a large population. Since the response is survival time, it is natural to
measure the beneficial treatment effect by the hazard ratio of TT relative to O. A minor complication arises
from the fact that in the particular probability model that we shall use a natural parametrization of hazard
ratios does not exist. In general hazard ratios depend on time. We define a hazard ratio as follows. Denote
by S(t, z,x,θ) = p(y ≥ t | z,x,θ) the survival function at time t for a patient with covariate vector x
under an assumed model with parameter vector θ. Similarly, H(t, z,x,θ) = − log{S(t, z,x,θ)} defines
cumulative hazard. Next, we define an average hazard
AH(z,x,θ) = H(T, z,x,θ)/T (2)
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for a chosen horizon T . In our implementation we fix T as the third quantile of the empirical distribution of
the observed PFS times in the data reported in IMPACT (Tsimberidou et al., 2012). Using the empirical dis-
tribution of xi, we define an AH for a mutation-tumor pair a as AHa(a, z,θ) = 1n(a)
∑n(a)
i=1 AH(z,xi,θ)
(no problem with zero division arises since we will only use AH for a with n(a) > 0). Here the sum goes
over all patients whose covariates fall within the mutation-tumor pair described by a (which typically fixes
one or several coordinates of xi) and n(a) denotes the number of such patients. Denote a pair-specific
hazard ratio
HR(a,θ) =
AHa(a,O,θ)
AHa(a, TT,θ)
.
HR(a,θ) = 1 means no difference of average hazard exists between O and TT for mutation-tumor pair a.
Under a Cox proportional hazard model for event times logHR(a,θ) would reduce to just the coefficient
for treatment. Finally, we assume that the model includes special cases for no treatment effect for any
patient (H0) and for the same treatment effect for all patients in the eligible population (H1). Here H0
and H1 are subsets of the parameter space. Formally, H0 = {θ : HR(a,θ) = 1 for all a} and H1 =
{θ : HR(a,θ) = c > 1 for all a}. One could relax the definition to allow for approximately equal to 1
and approximately constant treatment effect, respectively. Importantly, the upcoming discussion does not
require prior point masses, i.e., positive prior probability for H0 or H1. The choice of A is not directly
linked to posterior probabilities in the sampling model. It is possible that one might want to report A0,
i.e., no effect for any patient, even when H0 is almost surely not true. This could happen, for example, if
we find high posterior probability for a positive treatment effect, but the effect is clinically meaningless;
or when we find a moderate treatment effect, but for a very small subpopulation that is impractical for any
further drug development. Next we will introduce the notion of utilities as a way to formalize such relative
preferences.
We define a utility function,
u(A,θ) =

u0I(A = A0) if θ ∈ H0∑
a∈A
{
{log[HR(a,θ)]− β}fα(a)
}
otherwise
u1I(A = A1) if θ ∈ H1,
(3)
where fα(a) is a function on mutation-tumor pairs that penalizes for small subgroups and β > 0 is a fixed
threshold of minimum clinically meaningful difference in log hazard. The broad idea of u(A,θ) is to favor
the report of large subgroups with a meaningful treatment effect, and a preference for reporting the overall
null or alternative if appropriate. However, the specific formalization in (3) remains arbitrary. For example,
one could argue to replace log[HR(a,θ)] by log[HR(a,θ)] − log[HR(H1,θ)], that is a treatment effect
relative to an overall treatment effect. In the current application an overall treatment effect of targeted
therapy across all cancers and across all patients is a priori unlikely and can be ignored. For the same
reason we do not include a scaling of the payoff u1 by a possible overall treatment effect log[HR(H1,θ)].
In other applications such modifications could be useful.
The definition of fα(a) is based on the following considerations. Mutation-tumor pairs with small
n(a) should be penalized, as they are of less clinical interest and at the same time inference is subject to
substantial predictive uncertainty. In summary, we use
fα(a) =
{
0 n(a) < 5
n(a)α n(a) ≥ 5.
Here n(a) denotes the size of the subgroup that is characterized by a.
In this specification of the utility function, the constants (u0, u1, α, β) are tuning parameters. A prac-
tical implementation of the proposed design should use the following considerations to fix these tuning
parameters. The payoff u0 should be fixed to achieve a desired type I error rate. That is, the fraction of
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repeat simulations that do not conclude with reportingA? = A0 under repeated simulations of hypothetical
trial realizations under a simulation truth inH0. See the upcoming discussion of frequentist operating char-
acteristics for more details on setting up such repeat simulation. Similarly, u1 should be fixed to achieve,
or come close to, a desired true positive rate, that is, fraction of repeat simulations that end up concluding
with A? = A1 under a simulation truth in H1. The threshold β should be elicited from clinical collab-
orators. The power α relates to the relative importance of a large subpopulation. In the implementation
we used α = 1/8, corresponding to a weak preference for large subpopulations. Any value 0 ≤ α ≤ 1
is reasonable, with α = 0 implying no penalty for small subpopulations and α = 1 implying linearly
increasing utility for larger subpopulations. Keep in mind the constraint n(a) ≥ 5, ruling out excessively
small subpopulations.
Among alternative utility functions or criteria to select subpopulations used in the related literature are
weighted power (Graf et al., 2015) in the context of two or few subgroups under consideration; expected fu-
ture patient outcome (Simon and Simon, 2017) in the context of a binary outcome and parametric Bayesian
inference about the benefit of two competing treatments as a parametric function of baseline covariates;
and enhanced treatment effect in the reported subpopulation versus the overall population (Foster et al.,
2011). Graf et al. (2015) also include size of the proposed subpopulation in the utility function (penalizing
for large subsets when the treatment entails a safety risk). For IMPACT II we judged the proposed utility
function (3) to best formalize the intention of the study.
5 Sampling Model and Adaptive Allocation
5.1 Expected utility and Bayes rule
Recall that we assume that there exists a sampling model for the observed data, and that the model is
indexed by a parameter vector θ. Let y = (y1, . . . , yn) denote all observed outcomes, and let X =
{xi, zi, i = 1, . . . , n} denote the known covariates and treatment assignments. We write p(y | θ,X) for
the assumed sampling model. Now add one more assumption by completing the probability model with a
prior p(θ) for the unknown parameters, implying a posterior probability model p(θ | y,X). The utility
function u(A,θ), together with p(θ | y,X) determine the optimal report for a subpopulation as
A? = argmax
A
∫
u(A,θ) p(θ | y,X) dθ. (4)
In words, the solution A? is the subpopulation report that maximizes the decision criterion u(A,θ). Since
θ is unknown we average with respect to p(θ | y,X). One can argue from first principles that this is how
a rational decision maker should act (Robert, 1994). The expectation U(A) ≡ ∫ u(A,θ) p(θ | y,X) dθ,
after integrating out all unknown quantities, is known as expected utility, and the rule A? is known as the
Bayes rule.
5.2 Nonparametric Bayesian survival regression
In our implementation we define a nonparametric Bayesian survival regression using a model proposed in
Mu¨ller et al. (2011) and Quintana et al. (2014). A similar model is proposed in Hannah et al. (2011). The
model is based on a random partition of the experimental units [n] = {1, . . . , n}, in our case, the patients
in the study. That is, patients are arranged in clusters based on patient-specific covariates xi. To avoid
misunderstanding we note that this partition is unrelated to the population finding. Any alternative model,
without clustering, could be used. We briefly summarize the model below. For more details see Mu¨ller
et al. (2011); Quintana et al. (2014).
Let Sj ⊂ [n] denote the j-th cluster, j = 1, . . . , J , and let θ?j denote cluster-specific parameters. A
cluster-specific sampling model specifies p(yi | i ∈ Sj ,θ?j ). Let LN(y; µ, σ2) indicate a lognormal
distributed random variable y, that is, log(y) ∼ N(µ, σ2). In our implementation we use p(yi | i ∈
c© 2017 WILEY-VCH Verlag GmbH & Co. KGaA, Weinheim www.biometrical-journal.com
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Sj ,θ
?
j = (µj , σ
2
j )) = LN(yi; µj , σ
2
j ). Censored event times yi do not introduce any additional difficulty
in posterior inference. Inference will be implemented by Markov chain Monte Carlo (MCMC) posterior
simulation, which allows to easily accommodate censoring by imputing the missing event times. Averaging
over repeat imputation correctly marginalizes with respect to yi.
We complete the model description with a specification for the random partition p(S1, . . . , SJ |X) and
eventually a prior for θ?j . Let ρn = {S1, . . . , SJ} denote the random partition (including the unknown size
J). We use
p(ρn |X) ∝
J∏
j=1
g(x?j ) c(Sj), (5)
where x?j = {xi, i ∈ Sj}. This is a modification of the product partition model (PPM) p(ρn) ∝
∏
c(Sj)
of Hartigan (1990). With c(Sj) = M(|Sj | − 1)! the PPM reduces to the popular Polya urn model (Quin-
tana and Iglesias, 2003). In (5) we modified the model to include a factor g(x?j ), which is chosen to favor
clusters with similar xi. We refer to g(x?j ) as similarity function. Let Ri = {` : xi` 6= NA} denote
the set of recorded covariates for patient i and let x?j` = {xi`, i ∈ Sj and ` ∈ Ri}. Let g`(x?j`) denote
a similarity function for the `-th covariate. We then define g(x?j ) =
∏p
`=1 g`(x
?
j`). That is, we define a
product similarity function. For example, if xi were a single categorical covariate, say tumor type, letting
Mj denote the number of unique values xi for i ∈ Sj and g(x?j ) = 1/Mj would define a similarity func-
tion that favors homogeneous clusters with a single unique value xi in each cluster. See the appendix for
the similarity functions that we used in our implementation, and see Mu¨ller et al. (2011) for more discus-
sion. The described model implements a nonparametric Bayesian survival regression. Using latent clusters
the model allows to represent arbitrary interactions of covariates and treatment indicators. However, any
alternative survival regression that allows to learn about enhanced treatment effects, that is, that includes
treatment by covariate interactions, could be used. For example, one could use the BART survival regres-
sion (Sparapani et al., 2016) for which a computationally highly efficient implementation is available as an
R package.
5.3 Adaptive allocation
Adaptive treatment allocation in (1) requires the evaluation of pii as the posterior probability of superiority
of TT over O for patient i under the assumed probability model. Let y0i and y
1
i denote potential outcomes
for patient i if the patient were allocated to O or TT, respectively and let y = (y1, . . . , yi−1) and X =
{xh, zh, h < i} denote the data on the first i− 1 patients. Then the predictive distribution
p(y0i , y
1
i | xi,X,y) =
∫
p(y1i | xi, zi = TT,θ) p(y0i | xi, zi = O,θ) p(θ |X,y) dθ, (6)
takes the form of an expectation with respect to the posterior distribution. See the appendix for more details
on (6). The posterior probability of superiority then becomes
pii =
∫
y0i<y
1
i
dp(y0i , y
1
i | xi,X,y).
The attraction of this definition of pii is the evaluation with an available Monte Carlo sample, without the
need for any additional simulation. This makes it suitable for fast on-line evaluation, as will be needed for
an implementation of the proposed design when a clinical team has to rely on prompt and uncomplicated
evaluation of allocation probabilities.
Finally, we note that subpopulation finding and adaptive allocation are two separate features of the
proposed design. One could carry out subpopulation finding alone, without adaptive allocation and vice
versa. See, for example, Wathen and Thall (2017) or also Karrison et al. (2003) for recent discussions of
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the limitations of response-adaptive designs. In a large simulation study Wathen and Thall (2017) find only
little evidence for desirable properties of adaptive allocation methods. Our results are in line with these
observations (see Table 3, below).
6 Simulation and Operating Characteristics
6.1 Simulation setup
We carry out extensive simulation studies to evaluate the model and the subpopulation finding. We include
6 scenarios specifying different lognormal regressions with possible interactions among treatment, muta-
tions, and tumor types. Using a lognormal regression the simulation truth is deliberately selected to be a
different model than the assumed PPMx analysis model. We use 400 hypothetical patients. Table 1 shows
the assumed sample sizes, which are chosen to match the order of magnitude of estimates with the obser-
vational data in IMPACT trial. For each patient in the simulation we first generate a treatment indicator
zi with p(zi = 1) = 0.5 (zi = 1 for TT and zi = 0 for control). The response yi is then generated from
a lognormal regression model. Table 2 shows the assumed interaction effects for each of the six scenar-
ios. Let p (p = 1, 2 or 3 depending on the scenario) denote the number of interaction effects for a given
scenario, let βj denote the corresponding regression coefficient, and let mcij ∈ {0, 1} denote an indicator
whether patient i presents with the combination of mutation and tumor type for the j-th interaction. For
example, under scenario 4, β1 = 0.3 and mci1 = 1 for a patient with PIK3CA mutation and breast cancer.
We generate log(yi) ∼ N(β0zi +
∑p
j=1 βjzimcij , σ
2), where σ = 0.2. For each scenario, we simulate
500 trials.
BRCA Ovary Lung
FGFR 15 20 5
BRAF 10 100 60
PIK3CA 50 30 5
PTEN 13 25 5
MET 12 30 20
Table 1 Sample sizes in mutation-tumor pairs.
Scenario Overall trt Interactions
1 0 none
2 0.4 none
3 0 BRAF*Lung*z (0.4)
4 0 PIK3CA*BRCA*z (0.3), BRAF*Lung*z (0.3)
PTEN*Lung*z(0.4)
5 0 PIK3CA*BRCA*z (0.3), BRAF*Ovary*z (0.4)
BRAF*Lung*z(0.3)
6 0 BRAF*BRCA(0.4), BRAF*Ovary*z (0.3),
BRAF*Lung*z(0.4)
Table 2 Simulation truth for 6 scenarios. The 2nd column reports the true overall treatment effect, that is
the regression coefficient β0 of the treatment indicator zi in a lognormal regression model. The 3rd column
report interactions between tumor types, mutations and zi (if present). The values in parentheses are the
corresponding regression coefficients βj (j = 1, 2, or 3, for up to 3 interaction effects) in the simulation
truth.
We evaluate the proposed inference with respect to two decisions, the treatment allocation based on (1)
and the subpopulation reports (4). For both evaluations we report summaries under repeated simulations.
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That is, we assume a setup where the proposed design is used repeatedly for multiple trials and perfor-
mance is evaluated over these repeated simulations. Such summaries are known as (frequentist) operating
characteristics. We use them to calibrate tuning parameters in the utility function.
6.2 Adaptive allocation
Figure 2 plots the average percentage of patients randomized to TT and O for each mutation-tumor pair
with a corresponding treatment effect that is different from the overall population under the simulation
truth in scenarios 3-6. In scenario 3, where the pair (BRAF, Lung) has a favorable treatment effect, 68%
of Lung patients with BRAF mutation are randomized to TT, indicating that more patients receive their
superior treatment. In scenario 4, {(PIK3CA, BRCA), (BRAF, Lung), (PTEN, Lung)} are mutation-tumor
pairs with significantly higher treatment effects. For (PIK3CA, BRCA) and (BRAF, Lung), 70% and 60%
of all patients with these mutation-tumor pairs are randomized to TT, respectively. But for lung cancer
patients with PTEN mutation, only 51% are assigned to TT. The reason is that only n(a) = 5 patients
have mutation and tumor matching (PTEN, Lung), as shown in Table 1. The small sample size makes it
difficult to learn about the true effect. In scenario 5, we assume increased treatment effects for mutation-
tumor pairs {(PIK3CA, BRCA), (BRAF, Ovary), (BRAF, Lung)}. All three pairs include more than 50
patients. Figure 2 shows that more patients in these groups are allocated to their superior treatments.
Similarly for scenario 6. Figures S1 through S4 (in the supplementary file) show allocation probabilities
for all mutation-tumor pairs. In cases when the simulation truth assumes no differential treatment effect
the allocation probabilities are close to 0.5. When additionally the corresponding sample size is large, e.g.,
for (BRAF, Ovary), the allocation probabilities to TT under repeat simulations are narrowly centered at 0.5
(Figure S1).
6.3 Subpopulation finding
Next we evaluate rule (4) for subpopulation finding by summarizing, again over repeated simulations under
a hypothetical truth, using in turn each of the 6 scenarios. We record how accurately the proposed approach
reports true subpopulations. We have to first define what we understand under a true subpopulation. Let
θ0 denote the true sampling model under one of the 6 scenarios. We first compute the utility function
U0(A) ≡ u(A,θ0) for all possible subpopulationsA under the true sampling model. That is, we replace the
expectation in (4) by an expectation under the true sampling model. Note that under the fixed hypothetical
truth θ0 there is no uncertainty left on θ. Therefore U0 does in contrast to U(·) not involve any averaging
over θ. We then define the “true” subpopulation Atrue as the top subpopulation report with the largest
utility U0(A). The true subpopulation Atrue need not match any of the interactions in the simulation truth
in Table 2.
This separation of the statistical inference related to model fit and estimation versus the decision is
important. It is related to the difference between statistical significance versus practical relevance, but goes
beyond that. For the model fit we use a maximally flexible model that should ideally be able to fit higher
order interactions and more. In contrast, for the subgroup report we prefer a simple and parsimonious
solution. This preference is formalized by the utility function.
In each scenario, we compute the percentage of trials in which each subgroup a is reported:
Pr(a) =
1
500
∑
h
I(a ∈ A?h).
Here A?h is the report in repeat simulation h, h = 1, . . . , 500, using the Bayes rule (4). In words, Pr(a)
are estimated (frequentist) probabilities over repeat simulations and h indexes each simulation. Figure 3
shows Pr(a), that is A? (right panel in each pair of panels), versus the simulation truth U0(A) (left panel).
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Figure 2 The average percentage of patients allocated to O and TT in each mutation-tumor pair with
treatment effect different from the overall population under the simulation truth.
6.4 Operating characteristics
The utility function depends on the parameters u0, u1, α, and β. We fix these parameters to achieve a
desired error rate. For this purpose, we summarize several types of error rates. Recall that A0 indicates the
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Figure 3 In each scenario, the left panel shows the simulation truth. Blue cells represent mutation-tumor
pairs with treatment effect different from the overall population under the simulation truth; the right panel
shows a heatmap of Pr(a), the probability (under repeated simulation) of reporting each mutation-tumor
pair.
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decision not to report any recommended subpopulation and A1 indicates the decision to report the entire
patient population. And recall the notation A = {a : a = (ja, ca)} for any other subpopulation report. We
will use superscript c to denote the absence of a particular report in the list of pairs in each subpopulation
report. Finally, as before we use Pr to denote a frequentist rate of the various errors. That is, the probability
under repeated simulations. And we slightly abuse the notation of conditioning bar. In Pr(a | b), the first
argument, a refers to a decision, and the second, b, refers to an event under the simulation truth. For
example Pr(ac | a) = ∑h I(a /∈ A?h)/500 refers to the probability of not reporting mutation-tumor pair
a (a /∈ A?h) when the pair is in the true subpopulation, i.e., a ∈ Atrue. The probability is evaluated as
average over 500 repeated trials. When Atrue includes multiple mutation-tumor pairs the rates include an
average over all a ∈ Atrue, as indicated below.
We report the following six error rates: 1) Type 1 error (TIE) = Pr(Ac0 | H0); 2) TSR (true subgroup
rate) = Pr(a | a) = ∑
a∈Atrue
∑
h I(a ∈ A?h)/(500 × |Atrue|); 3) TPR (true positive rate) = Pr(A1 |
H1); 4) FSR (false subgroup rate) = Pr(a | ac) =
∑
a/∈Atrue
∑
h I(a ∈ A?h)/(500 × |(Atrue)c|); 5)
FNR (false negative rate) = Pr(A0 | Hc0); 6) FPR (false positive rate) = Pr(A1 | Hc1). The selection of
these error rates could be changed as desired. For example, for other applications it might be meaningful to
report expected (under repeated simulation) false discovery rates, etc. All unknown parameters in the utility
function (3) are calibrated to restrict TIE=0.05, shown in scenario 1 and TPR = 0.9, shown in scenario 2,
u0 = 1.3, u1 = 20, α = 1/8, and β = 0.4. Note that TIE and TPR are special cases of TSR, and FNR and
FPR are special cases of FSR. Not all error rates are meaningful in all scenarios. For example, TIE is only
meaningful when H0 is in fact the true population under U0(A) and similar for TPR. Table 3 summarizes
the 6 error rates in the 6 scenarios.
Scenario TIE TSR TPR FSR FNR FPR
1 0.05 - - - - -
2 - - .90 - - -
3 - .87 - .04 .10 .00
4 - .68 - .04 .04 .00
5 - .77 - .02 .01 .00
6 - .77 - .02 .04 .00
3 (without AR) - .86 - .01 .14 .00
Table 3 Simulation operating characteristics results. The table shows six different error rates for the
subpopulation finding report, including TIE = Pr(Ac0 | H0); TSR = Pr(a | a); TPR = Pr(A1 | H1); FSR
= Pr(a | ac); FNR = Pr(A0 | Hc0); and FPR = Pr(A1 | Hc1). AR denotes adaptive randomization.
Finally, we investigate the effect of the adaptive randomization (AR). We consider scenario 3 in the sim-
ulation study, but now without AR. The results are reported as an additional line in Table 3. Compared to
the simulation with AR the changes are small. This is probably due to the fact that adaptive randomization
is conservative (bounded by p0 and p1, respectively), the sample size is moderate in each subpopulation,
and the model includes borrowing of strength across different subpopulations.
6.5 Inference and Comparison
For comparison, we implement two alternative trial designs: a simple two-arm randomization (NAIVE)
and separate trials for each molecular aberration (SEPARATE). NAIVE assigns patients equally to TT and
O, and compares TT with O over the whole population. In particular, no subgroups are considered in
the NAIVE design. In the NAIVE design, we assume log(yi) | zi ∼ N(µzi , σ2zi) with conjugate priors
µzi ∼ N(µ0, τ2) and σ2zi ∼ Inverse Gamma(b1, b2), where zi = TT or O. In the SEPARATE design, we
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perform separate independent studies for each subgroup determined by mutation only, that is, “rows” in
Figure 3. In other words, SEPARATE are five separate trials with the NAIVE design.
We compare the three methods based on the expected PFS time of a hypothetical future patient who
is assigned the optimal treatment as estimated from these three methods. Subtracting (true) expected PFS
under O, any comparison of expected PFS under the optimal treatment under different designs can equiva-
lently be interpreted as a difference in treatment effects, defined as difference under optimal treatment and
O (thus the acronym TE, below). Let Ey denote an expectation with respect to y under the simulation
truth, and then define TE(x, z) = Ey(y | x, z) to be the expected treatment effect for a future patient with
covariate x under treatment z. Let TEx = TE(x, z∗x) be TE under the optimal treatment z
∗
x for a patient
with covariate x, as inferred from posterior inference under the analysis model. For instance, the optimal
treatment for patients in the reported subpopulation A∗ in (4) is TT, otherwise O. Similarly let Ey|X de-
note an expectation over y with respect to the posterior predictive distribution (under the analysis model),
and let T̂E(x, z) = Ey|X(y | x, z) denote the estimated T̂E under treatment z and T̂Ex = T̂E(x, z∗x).
For NAIVE and SEPARATE designs, we compute the optimal treatment for a patient with covariate x as
z∗x = argmaxzT̂E(x, z). That means, if T̂E(x, z = TT) > T̂E(x, z = O) then z
∗
x = TT; otherwise
z∗x = O. Finally, we define TEa = TEx for x = (m, c) with c = ca,mja = 1, and mj = 0, j 6= ja
to be the expected PFS for the mutation-tumor pair a = (ja, ca) under the simulation truth and T̂Ea to be
the estimated PFS. And, again, subtracting true PFS under O, each of these summaries can be considered
a summary on treatment effects.
Figure 4 plots |T̂Ea−TEa| for each mutation-tumor pair under the three methods: NAIVE, SEPARATE,
and OURS in scenarios 3-6. OURS refers to the proposed approach. We find that OURS reports the
smallest differences among all mutation-tumor pairs in scenarios 3-5. SEPARATE performs slightly better
than OURS in scenario 6 since the simulated true mutation-tumor pairs ({(BRAF, BRCA), (BRAF, Ovary),
(BRAF, Lung) }) with treatment effect different from the overall population happen to match the analysis
model of SEPARATE, which considers the subgroup by mutation only.
7 Conclusion
We have outlined a Bayesian adaptive clinical trial design to assign patients to their superior treatment and
a practicable decision theoretic approach to optimal subpopulation finding. The strengths of the proposed
approach include: 1) we make decisions based on a flexible utility function that reflects the requirement of
the clinicians appropriately and realistically, such as rewarding the correct subpopulation reports and penal-
izing small size subpopulations; 2) we use a general class of probability models that efficiently incorporate
treatment covariate as well as covariate-covariate interactions.
Some limitations remain. For example, the solution of the proposed decision theoretic approach depends
on the often arbitrary choice of the unknown parameters in utility function. The problem is mitigated by
calibrating frequentist operating characteristics like TIE.
Finally, we note that the proposed approach was introduced in an oncology trial, but is of course valid in
any other disease area. Similarly, we introduced specific choices for the utility function, sampling model,
and prior. But others could be used, including in particular, informative priors when available. In the
nonparametric Bayesian survival regression that we used the easiest way to include informative priors is to
include hypothetical additional patients in the data for posterior computation.
Appendix: The PPMx model
Similarity function. Mu¨ller et al. (2011) propose a generic construction of similarity functions in (5)
based on an auxiliary probability model q(x?j | ξ?j ) and q(ξ?j ). Here ξ?j are additional parameters used
for the definition of the similarity function. Importantly, the model q(·) is used only to obtain an easy
expression for the similarity function, without any notion of modeling a distribution of covariates xi. We
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Figure 4 The differences between the estimated treatment effect and true treatment effect for each
mutation-tumor pair under NAIVE, SEPARATE, and OURS in scenarios 3-6.
define g(x∗j ) =
∫ ∏
i∈Sj q(xi | ξ?j )q(ξ?j ) dξ?j , which can be interpreted as the marginal model under q(·),
and can be analytically evaluated when the distributions are chosen as conjugate pair. The definition is
meaningful when the marginal is highest for sets of covariate values x?j that would be considered to be
similar, as is the case under most models.
For continuous xi we define ξ?j = (µj , vj). Let q(xi | ξ?j ) = N(xi | µj , vj), and q(µj , vj) be the
conjugate normal-inverse chi-square (or gamma) prior distribution (see, for example, Gelman et al., 2004).
Then g(x∗j ) is a scaled and correlated nj-dimensional multivariate t density. Here nj = |Sj | is the size
of the j-th cluster. Next, consider a categorical covariate xi with c levels, xi ∈ {1, . . . , c}. Let ξ?j =
(pi1, . . . , pic) where 0 ≤ pir for all r = 1, . . . , c and
∑c
r=1 pir = 1. Then use q(xi | ξ?j ) ≡ mult(xi | 1, ξ?j )
and q(ξ?j ) ≡ Dir(ξ?j | α) for some suitable choice of α. In this case, q(ξ?j | x∗j ) is again a Dirichlet
distribution, and g(x∗j ) is a Dirichlet-multinomial distribution. In the particular binary case (c = 2) we
get the beta-binomial distribution. For Count covariates, we define q(xi | ξ?j ) as a Poisson distribution
with rate ξ? > 0, and for q(ξ?) we assume a gamma distribution. Then, q(ξ?j | x∗j ) is again a gamma
distribution and g(x∗j ) reduces to the Poisson-gamma distribution.
Under all three cases we can exploit the conjugate nature of q(·) and use Bayes theorem to evaluate
g(x∗j ) =
∏
i∈Sj q(xi | ξ˜?j )q(ξ˜?j )
/
q(ξ˜?j | x?j ), where ξ˜?j is any fixed value of ξ?j . Note that this expression
can be readily evaluated and the dimension of ξ˜?j does not depend on the cluster size.
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Posterior predictive inference. In (6) we use the posterior predictive distribution under the assumed
model. We briefly describe p(yn+1 | xn+1, zn+1,y,X) (recall thatX includes the treatment assignments
z1, . . . , zn) under the PPMx model. In words, the posterior predictive distribution averages with respect
to the cluster membership for i = n + 1, with respect to the posterior distribution on the cluster-specific
parameters θ? and finally, with respect to the posterior distribution on the random partition. The latter
average reduces to a sum over all possible partitions of [n].
As before, let ρn = {S1, . . . , SJ} denote the random partition (including the random size J of the
partition). That is, there are J clusters S1, . . . , SJ with
⋃J
j=1 Sj = [n]. Let x
?
j = {xi, i ∈ Sj} denote
the covariates arranged by clusters. We first match i = n + 1 with one of the J current clusters based
on matching xn+1 with x?j . Conditional on n + 1 ∈ Sj and conditional on θ? the prediction for yn+1 is
p(yn+1 | n+ 1 ∈ Sj ,θ?j ) = LN(µj , σ2j ). The desired predictive distribution p(yn+1 | xn+1, zn+1,X,y)
is then defined by averaging p(yn+1 | n + 1 ∈ Sj ,θ?j ) with respect to the cluster-specific parameters and
with respect to the random partition. In summary,
p(yn+1 | xn+1, zn+1,X,y) =
∑
ρn
p(ρn |X,y)
∫
p(θ? | ρn,X,y)
×

J+1∑
j=1
p(yn+1 | n+ 1 ∈ Sj ,θ?j ) p(n+ 1 ∈ Sj | xn+1, zn+1,X, ρn)
 dθ?.
The innermost sum is the average with respect to the cluster membership for the (n+1)-st patient. Note that
the cluster membership includes a regression on xn+1. We allocate the next patient with higher probability
to existing clusters Sj with similar covariates x?j . Also note that the average includes j = J + 1, that is,
the possibility that (n+ 1) forms a new (singleton) cluster SJ+1 = {n+ 1}.
Software. In implementation of the proposed design as R macros can be found at http://www.ams.
jhu.edu/˜yxu70/software.html.
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